Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1E | P28566 | 2/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.48 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7567363 | 1.00 | HTR1E (0.49) | HTR1ES1PR3MEN1LMNAMAPT | |
| SCHEMBL7568224 | 0.81 | SOAT2 (0.56) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7568088 | 0.81 | SOAT2 (0.56) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7574751 | 0.80 | SOAT2 (0.55) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7569983 | 0.77 | SOAT2 (0.55) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7573089 | 0.75 | SOAT2 (0.53) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7566736 | 0.75 | SOAT2 (0.60) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7574471 | 0.74 | SOAT2 (0.58) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7574816 | 0.73 | — | — | |
| SCHEMBL7575399 | 0.72 | SOAT2 (0.54) | SOAT2MYCSOAT1MAP2K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | disclosed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | HTR1E 4055/4885S1PR3 2432/4885MEN1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.